GlassScriptPhysician profile
Dortha T Chu
NPI 1629227251
$3,424.51
in general payments reported to CMS, 2019-2025
25 companies · $54.41 in 2025
The $54.41 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $783 · 2021: $443 · 2022: $465 · 2023: $587 · 2024: $381 · 2025: $54.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $719.23 | 2019-2023 | Evenity |
| Bioptics, INC. | $508.68 | 2020 | |
| Merck Sharp & Dohme LLC | $389.07 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $384.99 | 2019-2024 | |
| Endomagnetics LTD | $194.69 | 2023 | Magtrace, Magseed |
| Eisai INC. | $169.75 | 2019-2024 | |
| Foundation Medicine, INC. | $150.00 | 2020 | |
| Gilead Sciences, INC. | $124.99 | 2023 | Trodelvy |
| Janssen Pharmaceuticals, INC | $116.67 | 2019 | |
| Medtronic USA, INC. | $112.53 | 2019 | |
| Beigene USA, INC. | $95.41 | 2022 | |
| Myriad Genetic Laboratories, INC. | $86.04 | 2021 | |
| Lilly USA, LLC | $52.69 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $46.34 | 2019-2023 | Venclexta |
| Boston Scientific Corporation | $41.45 | 2024 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $40.00 | 2019 | |
| Emd Serono, INC. | $30.70 | 2024 | |
| Pharmaessentia USA Corporation | $25.38 | 2024 | Besremi |
| Sumitomo Pharma America, INC. | $23.19 | 2024 | Orgovyx |
| Agios Pharmaceuticals, INC. | $20.55 | 2024 | Pyrukynd |
| Tactile Systems Technology INC | $20.46 | 2025 | Flexitouch Plus, Nimbl |
| E.R. Squibb & Sons, L.L.C. | $20.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.84 | 2024 | |
| Btg International INC. | $17.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.30 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dortha Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.